Pulike Biological Engineering, Inc.

SHSE:603566 Stock Report

Market Cap: CN¥4.3b

Pulike Biological Engineering Future Growth

Future criteria checks 4/6

Pulike Biological Engineering is forecast to grow earnings and revenue by 26.2% and 13.7% per annum respectively. EPS is expected to grow by 26.4% per annum. Return on equity is forecast to be 9.5% in 3 years.

Key information

26.2%

Earnings growth rate

26.4%

EPS growth rate

Pharmaceuticals earnings growth18.1%
Revenue growth rate13.7%
Future return on equity9.5%
Analyst coverage

Good

Last updated10 Jul 2024

Recent future growth updates

Recent updates

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21
Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28
Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21
Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28
Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

SHSE:603566 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,745309N/A4066
12/31/20251,567283N/A3437
12/31/20241,389224N/A2327
3/31/20241,1811383246N/A
12/31/20231,253175-22283N/A
9/30/20231,329225-144251N/A
3/31/20231,292194-148269N/A
12/31/20221,230168-129228N/A
9/30/20221,105142-124252N/A
6/30/20221,032161-90271N/A
3/31/20221,035195-129219N/A
12/31/20211,099244-105213N/A
9/30/20211,10229842245N/A
6/30/20211,08627135218N/A
3/31/20211,04425562245N/A
12/31/202092922885262N/A
9/30/202084017562218N/A
6/30/202076516484205N/A
3/31/202070915495191N/A
12/31/201966310955140N/A
9/30/201964811255136N/A
6/30/20196421241384N/A
3/31/20196121113591N/A
12/31/201860813673126N/A
9/30/201858014192135N/A
6/30/2018557129107159N/A
3/31/201854111980134N/A
12/31/2017530114N/A141N/A
9/30/2017537124N/A218N/A
6/30/2017592160N/A209N/A
3/31/2017599178N/A225N/A
12/31/2016583188N/A253N/A
9/30/2016543181N/A206N/A
6/30/2016505161N/A193N/A
3/31/2016465139N/A187N/A
12/31/2015478142N/A187N/A
9/30/2015467152N/A166N/A
6/30/2015486158N/A165N/A
3/31/2015499161N/A148N/A
12/31/2014476140N/A151N/A
12/31/2013472163N/A181N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603566's forecast earnings growth (26.2% per year) is above the savings rate (2.9%).

Earnings vs Market: 603566's earnings (26.2% per year) are forecast to grow faster than the CN market (22.1% per year).

High Growth Earnings: 603566's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603566's revenue (13.7% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 603566's revenue (13.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 603566's Return on Equity is forecast to be low in 3 years time (9.5%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.